Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ligelizumab extension retreatment and self-administration study in chronic spontaneous urticaria
2019-001792-37Phase 3Terminated
- Sponsor
- Novartis
- Start
- Feb 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, double-blind, single-arm trial of ligelizumab in chronic idiopathic urticaria (CIU), sponsored by Novartis. Primary endpoint: Proportion of subjects with well-controlled disease at Week 12. Started Feb 2020; status: terminated.
02
Drugs
ligelizumab
03
Conditions
chronic idiopathic urticaria (CIU)
Beyond the preview
Go deeper on 2019-001792-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001792-37.